Overview

First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845

Status:
Completed
Trial end date:
2018-03-29
Target enrollment:
Participant gender:
Summary
This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845 using a placebo controlled, randomized, single center design.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer